Maiden Holdings, Ltd. 6.625 NT 2046
NYSE:MHLAInsurance - Property & Casualty
+$0.00 today
- Market cap
- $788.25M
- Beta
- 0.45
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$1.68
- Dividend yield
- 14.50%
Volume 0.00M
Average 0.00M
MHLA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Maiden Holdings, Ltd. 6.625 NT 2046NYSE: MHLA
Research & Development · Q1 FY2025 · quarter ended Mar 2025
Research & development remains negative
Q1 FY2025 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2024, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2024 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2024
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
| FY2020 | 2020-12-31 | 0 | — |
Research & Development vs competitors
How MHLA compares with its peers on the latest reported figures
- MHLA's LTM Mar 2025 research & development of $0 is the highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for MHLA, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2025 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| FY2025 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MHLA) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for MHLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 |
|---|---|---|---|---|---|
| Revenue | 184.12M | 98.72M | 58.13M | 89.23M | 56.44M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 184.12M | 98.72M | 58.13M | 89.23M | 56.44M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 39.12M | 36.02M | 30.95M | 30.8M | 35.35M |
| Operating Expenses | 39.12M | 36.02M | 30.95M | 30.8M | 35.35M |
| Depreciation & Amortization | 6.24M | 3.45M | 49.32M | 2.75M | 233K |
| EBITDA | 14.27M | 96.71M | 104.99M | 119.62M | (180.42M) |
| EBITDA Margin | 7.7% | 98.0% | 180.6% | 134.1% | -319.7% |
| Operating Income | 145.01M | 62.7M | 27.19M | 58.44M | 21.09M |
| Operating Margin | 78.8% | 63.5% | 46.8% | 65.5% | 37.4% |
| Interest Income | 0 | 19.33M | 19.33M | 18.23M | (201.61M) |
| Interest Expense | 19.32M | 0 | 0 | 0 | 19.27M |
| Other Income / Expenses | (103.35M) | (36.04M) | (87.78M) | (96.81M) | (221M) |
| Income Before Tax | 41.66M | 26.66M | (60.6M) | (38.37M) | (199.91M) |
| Pre-Tax Margin | 22.6% | 27.0% | -104.2% | -43.0% | -354.2% |
| Income Tax Expense | (104K) | 15K | (557K) | 196K | 1.06M |
| Net Income | 41.76M | 26.65M | (60.04M) | (38.57M) | (200.97M) |
| Net Margin | 22.7% | 27.0% | -103.3% | -43.2% | -356.1% |
| EPS (Basic) | 0.93 | 1.35 | 0.63 | (0.38) | (2.01) |
| EPS (Diluted) | 0.93 | 1.35 | 0.63 | (0.38) | (2.01) |
| Weighted Avg Shares | 84.49M | 86.39M | 87.49M | 101.38M | 99.9M |
| Weighted Avg Shares (Diluted) | 84.33M | 86.07M | 87.11M | 101.38M | 99.9M |
Maiden Holdings, Ltd. 6.625 NT 2046
NYSE:MHLA
Intrinsic Alpha fair value
Locked
Current Price
$9.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.